However, trends for improved 3-year DFS (80% versus 65%; HR = 0.6 (95% CI, 0.3 to 1.1); P = 0.09) and 3-year OS (90% versus 83%; HR = 0.4 (95% CI, 0.1 to 1.0); P = 0.04) with the addition of cetuximab to FOLFIRI were observed in patients with resected stage III CRC regardless of KRAS status [34]. The gene discussed is KRAS; the disease is colorectal carcinoma.